Compare FDP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | AUPH |
|---|---|---|
| Founded | 1886 | 1993 |
| Country | Cayman Islands | Canada |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1999 | 2014 |
| Metric | FDP | AUPH |
|---|---|---|
| Price | $41.11 | $15.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 187.0K | ★ 946.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | 1.88 | ★ 2.07 |
| Revenue | ★ $4,322,300,000.00 | $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | $3.14 | $15.74 |
| P/E Ratio | $22.37 | ★ $7.47 |
| Revenue Growth | 0.98 | ★ 20.38 |
| 52 Week Low | $31.85 | $7.29 |
| 52 Week High | $43.58 | $16.88 |
| Indicator | FDP | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 48.47 |
| Support Level | $40.04 | $14.56 |
| Resistance Level | $43.06 | $16.32 |
| Average True Range (ATR) | 0.89 | 0.51 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 35.96 | 30.83 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.